Evidence for "response to injury" hypothesis.
Role of platelet-derived growth factor (PDGF) in myointimal thickening described in "response to injury" hypothesis was investigated with artery of rats in culture and with air-injured artery of rats. PDGF promoted cell growth in ring preparation of carotid artery in culture denuded with citrate. It did not promote any cell growth in preparations without denudation. Trapidil, a PDGF antagonist, inhibited the cell growth promoted by PDGF in the denuded arterial ring. Systemic injection of PDGF was performed for 8 days to rats with thrombocytopenia induced by injections of anti-platelet serum. This treatment caused myointimal thickening of carotid artery 10 days after denudation by means of air injury. Trapidil at oral intake levels of 1, 3 and 30 mg/kg/day inhibited this change observed in denuded site of artery. Trapidil at oral intake of 6 mg/kg/day also inhibited myointimal thickening observed 15 days after denudation of carotid artery by air injury in normotensive and spontaneous hypertensive rats both with normal platelet counts. These results evidenced the role of PDGF in myointimal thickening described in "response to injury" hypothesis and clinical use of trapidil may be a new approach to the treatment of atherosclerosis.
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology; D001792:Blood Platelets / Q000276:immunology; D002339:Carotid Arteries / Q000166:cytology; D020212:Carotid Artery Injuries; D002455:Cell Division / Q000187:drug effects; D006133:Growth Substances / Q000494:pharmacology*; D006973:Hypertension / Q000503:physiopathology; D007106:Immune Sera / Q000494:pharmacology; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count; D010982:Platelet-Derived Growth Factor; D011743:Pyrimidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013921:Thrombocytopenia / Q000503:physiopathology; D014192:Trapidil / Q000494:pharmacology* / Q000627:therapeutic use
D006133:Growth Substances; D007106:Immune Sera; D010455:Peptides; D010982:Platelet-Derived Growth Factor; D011743:Pyrimidines; D014192:Trapidil